-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QeEHGLjUjF/Kf46kojCsMORmBHCj4PPkdvtJQ4c9ovVqeGbLAPdhYb6G9AzkSR2v SFeYkjr0JaIkDrm0RTyiAg== 0000000000-06-026728.txt : 20061017 0000000000-06-026728.hdr.sgml : 20061017 20060608092820 ACCESSION NUMBER: 0000000000-06-026728 CONFORMED SUBMISSION TYPE: UPLOAD PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060608 FILED FOR: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: UPLOAD BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6165776000 PUBLIC REFERENCE ACCESSION NUMBER: 0001047469-06-003585 LETTER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C0-)>+CS],-"C8S(#`@;V)J/#PO2%LU,38@,34T72],:6YE87)I M>F5D(#$O12`S.3`S+TP@,3`V,CDO3B`Q+T\@-C8O5"`Y,S(R/CX-96YD;V)J M#2`@("`@("`@("`@("`@("`@("`@("`@#0IXF4@-S0O4')E=B`Y,S$Q+UA29693=&T@-C')E9@T*,`T*)25%3T8-"B`@(`T*-C4@,"!O8FH\/"],96YG=&@@-S$O1FEL M=&5R+T9L871E1&5C;V1E+T,@.#DO3"`W,R]3(#,X/CYS=')E86T-"GC:8F!@ M8&=@8)['``3<[`RH@`F(61@X&IB1Q-BAF('!AX%;L'6=CFBCFY8#3+E0#E2; M!1`S,C#P+870S,%LW(#4V73X^%LP(#`@-C$R(#%LP M(#`@-C$R(#'1'4W1A=&4\/"]'4S`@ M-S(@,"!2/CX^/B]3=')U8W1087)E;G1S(#`^/@UE;F1O8FH--C<@,"!O8FH\ M/"]4>7!E+T9O;G0O16YC;V1I;F3FK?J4J4]-;2G*NH'#N.8UC81X.327]]9EM3!!NQ&D8,I%BH4+4HX;$"88LLM`@EZ.&Y!%#,K1@C&&A1<%'+:D3*&G!+**( M1@WI$PQ)RZQ`.>YMTVL(&2*&+K"SM^U+-Y9&*&85JB8$#\'O>0(W25KEZVD4 MY*L,DLT(%=KK5BDT)IQ_B?4E5;((H.1&K?47UB"A=H1?'=X)4`+PR++L8U2 M\S=DM[_,&K=*OG.QV^^[@$NZPWT5WQ;5`^HI?+/%O`]?2!2G=H9@=L#G%UR-!R)3SN9;*>VN#;E`=E M/G_,SDBUJBI)E]LJJ^L**$0RFBE!CP\RV=,'/EII2I%0"*['NX7`?ION2'IW M.GUH7I#T6^XU\R'X-?L`TQD7&CN1_K]A%GR8CMK148=TN.L57+>]@KB(D+C< M%.6:U'#V$RR*$F[RBJC`'UE2PO5F3CRNLC1;?Z/\E[Q1.3W,3`PS&Y94QPRI MN2#7X1XSZF!SRH$R75*5O4GL$+CL!>_@2$O3@>'F$`9^+A@0MQF/).70(,B` MI/6GEPQ='^+F2'J-Z-9H>DGM^A`W?D2Y(4KK6Q6V;K%])#S,JG@"6I$F0%DXHGD@H5IFK ME6);0ID]Y]D+%`MX=9D9G]EN#&I>W!2PV);UDM+9VW"?QO"&!*8)>R/6 MZAR"IH5[F%=3-J)6QX90Y?0IR;D77^`0>29EC4Q!9 M$M;U-('C`ZSLGX(.>[^S&+IN)7R7?&A[/\#]E&[P(*=%V6`S;6HJ=5<)2D9 MS4IJ?*:5_:K2'P0>,2Z$[L;@UGNVC<':N912WWOV![>(H/;W_O9?=J-5^=<+ M?[4Y%I$3?O4(U(S:NM[+E99+FQUI!W;;06_I=GD^OC%KE@MOK$VNQ!OKYM^R M\\*E?V'9<4&;E`OWI=P[]+\"#`!N"V?*#0IE;F1S=')E86T-96YD;V)J#38Y M(#`@;V)J/#PO5'EP92]&;VYT+T5N8V]D:6YG+U=I;D%N%LM-38X("TS,#<@,C`R."`Q,#`W72]&;VYT3F%M92]4:6UE7!E+T9O M;G1$97-CB/+H)^$#TD0`\VQ1GR&5(O94^MC$K* M&J,:Y5.%)Q5,4-:JX+RR3E5UK:Q7C3?*!M4D[$5$>211=..418`-<+#D`+(- M;`S*X=&;I)R%C4XYA`93*>*&RBA'*,`<>+&&#T1%/G@5^>#5Y(-7(YXJ2"8J M#UZ*\,%+#7SPF@`?O";!1XI!L,=1IH9?HP04XZF4"GZ#4J8^86-4P:(D\E&B M)]^C-/01T$((\,$+#7SP(N`!O)C@@U>A^``>U1NIA:91$;P:S5#+=:Q5!"^A M>7HE*<&GEK`9P6N25PCQ!N\V)E@<%J&$13W4LD5QE86MH81#R\:K5Z_T\GZ3 M]6(LN^MQ67*^&(91SZ&C41?Z:-UNMQ_;#00E][PMN9^B2-O]E=/\=9SG>V7U MQ;#.E`/=$3*;X8P/;;]Z\>;TE[>'/^OY)48`&S0"DXEL*C8UF\1F.I?4GXQE MX]@PQ3'%,<4QQ3'%,<4QQ3/%,\4SQ3/%,\4SQ3/%,\4SQ3,E,"4P)3`E,"4P M)3`E,"4P)4R4W_6YFGR]T(M\/4YOYW0H=^V:-'E\7Z>[N^VEH4^&\R/T'2?A@SXO#K37_S["P^ MM5#_N%OM2M8G/2'WEI9G!_@Y(GM"#_3K^&'E^&%EL=ODLKTNW6;DW-=EV!RUF\<3WF'\J)7/O'O>KO)/SN`%7.4R+Y'[X2!=/"RM554\S-,>GB"PCS7+(BHTTRU-6DF8%RJJE69&R*FE6 M15E1FE4+8A.=$*0G-)3EQ=K22$0G3J.9B/))#)#A*@BM)L$1Q MFR3!C>0K-))@*PF6:.F\)%BBH),HZ"0*NAKS%\1_P9Q$2R?1TDNT]!(MO41+ M+]'22[3T_U[+,]P%[^DN0%>5$UQC^A'_/5^:;SN0;$8 MAS]YS[0ICJZ+U_DPWPXE3_N3?W`[YO(4_IP]F_TAP`"#;-^5#0IE;F1S=')E M86T-96YD;V)J#3(@,"!O8FH\/"].=6US6S`@,R`P(%)=/CX-96YD;V)J#3,@ M,"!O8FH\/"]3+T0^/@UE;F1O8FH--"`P(&]B:CP\+T-O=6YT(#$O2VEDFMC.60G M/SX*/#]A9&]B92UX87`M9FEL=&5R&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G('@Z>&UP=&L])UA-4"!T;V]L M:VET(#(N.2XQ+3$S+"!F&UL;G,Z:5@])VAT='`Z+R]N&UL;G,Z<&1F>#TG:'1T<#HO M+VYS+F%D;V)E+F-O;2]P9&9X+S$N,R\G('!D9G@Z0V]M<&%N>3TG4V5C=7)I M=&EE#I3;W5R8V5-;V1I M9FEE9#TG1#HR,#`V,#4R-3$W-3$P,"&%P.D-R96%T;W)4;V]L/2=!8W)O8F%T(%!$1DUA:V5R(#8N,"!F;W(@5V]R M9"<@>&%P.DUO9&EF>41A=&4])S(P,#8M,#8M,#A4,#DZ,C8Z,#&UL;G,Z>&%P34T])VAT='`Z+R]N&%P+S$N,"]M;2\G M('AA<$U-.D1O8W5M96YT240])W5U:60Z,C@V8C=F,3&%P34TZ5F5R&UL;G,Z9&,])VAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT&UL.FQA;F<])W@M9&5F875L="<^,3DS-"!!0U0@15A!34E. M051)3TX@4D503U)4("`@(#PO'!A8VME="!E;F0])W&-H86YG92!#;VUM:7-S:6]N*2]3 M;W5R8V5-;V1I9FEE9"A$.C(P,#8P-3(U,3')E9@T*,3$V )#0HE)45/1@T* ` end -----END PRIVACY-ENHANCED MESSAGE-----